GENE ONLINE|News &
From AI to Precision Medicine: Taiwan’s Smart Healthcare Pavilion Showcases 10 Global-Ready Innovators at Taiwan Expo USA 2025
Organized by TITA and TAITRA, the Smart Healthcare Pavilion at Taiwan Expo USA 2025 in Dallas featured 10 leading organizations. Image: GeneOnline
At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion showcased Taiwan’s growing strength in digital health innovation. Organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), the pavilion featured 10 leading organizations that revealed new approaches in telemedicine, artificial intelligence (AI), precision medicine, and medical services. The exhibition declared Taiwan’s ambition to position itself as a global partner in advancing smart healthcare solutions.
Smart Hospitals: Leading the Charge in Clinical AI
Two of Taiwan’s flagship medical centers—both recognized in Newsweek’s World’s Best Smart Hospitals 2025—revealed new AI-driven diagnostic tools:
Taichung Veterans General Hospital (TCVGH) presented TAIMedImg PHDS, a patented ECG-based system capable of screening and predicting pulmonary hypertension without the need of invasive tests. The platform has been validated across multiple domestic medical centers and international hospitals and is shaping the future of non-invasive cardiovascular diagnostics. VeriOsteo OP, the AI-assisted software for bone mineral density (BMD) prediction and osteoporosis screening. It analyzes chest X-rays to provide estimated-BMD, which is used to convert to T-scores, and provide risk assessment of osteoporosis. It supports healthcare professionals in identifying BMD abnormalities and guiding referral decisions.
“Our primary objective is to establish strategic collaborations. We are specifically seeking partners in three key areas: hospital systems to facilitate the deployment of VeriOsteo OP in clinical settings, pharmaceutical companies offering osteoporosis-related services or therapies, and technology firms to assist in building an image platform. TCVGH’s future vision for smart healthcare is centered on the “3 Ps”: personalized medicine, preventive medicine, and predictive medicine” Yuan-Hwa Chou, Deputy Superintendent of TCVGH, stated.
Chang Gung Memorial Hospital, Linkou has developed several exciting AI models and systems. Their digital pathology platform has increased diagnostic sensitivity to 96%, earning high confidence from pathologists. They also have ECG AI for predicting left ventricle dysfunction and atrial fibrillation, crucial for preventing strokes. In addition, an AI-powered aortic dissection detection software rapidly classifies cases into Type A or Type B and alerts physicians, shortening the time to emergency intervention and improving survival.
“A newly developed AI model for newborn developmental dysplasia of the hip (DDH) echo imaging is currently under clinical validation and seeking US hospital collaboration for further verification and FDA approval. Beyond AI, we established the world’s first 5G ambulance for transferring critical pediatric patients, transmitting real-time patient data and vital signs to the hospital via 5G for remote monitoring.” Ming-Shien Wen, Consultant Cardiologist, emphasized.
AI-Powered Applications: Revolutionizing Clinical Workflows
Taiwan’s AI companies are demonstrating how clinicians visualize, diagnose, and assess patient health:
Lixel Inc. has demonstrated medical visualization using its glasses-free 3D floating images and air-touch technology, which can convert anatomical structures—after software-based segmentation and reconstruction—into 3D floating images on hardware devices, enabling touch-free interaction. The system integrates proprietary displays with AI-powered DICOM processing to deliver realistic 3D anatomy, supporting education, patient communication, surgical planning, and telemedicine. Already collaborating with major hospitals and medical schools in Taiwan, the company is now seeking U.S. partners for clinical adoption and regulatory support. “Our goal is to make a real impact on education and practice,” added Alex Yang, Co-Founder and CEO.
V5med Inc. has adapted its semiconductor imaging expertise to healthcare, developing an AI platform that enhances lung cancer screening via low-dose CT scans. Its model also detects COPD and lung fibrosis while integrating predictive functions, which the company views as the next frontier for AI in medicine. After proving its model through cooperation in South Asia, V5med is now targeting the U.S. market. “We want AI to move beyond diagnosis to prediction and prevention.” Julia Chang, Sales Director, remarked.
Shennona Co., Ltd. is advancing rehabilitation with its OpenShoulder System, a platform combining AR software, a resistance band, and a smart shoulder wheel to support recovery from shoulder dysfunction and surgery. Pilot programs in Taiwan have shown strong acceptance from therapists and patients, and the company is pursuing partnerships with clinics, health tech firms, and insurers to expand into home-based rehabilitation. “Our aim is to merge clinical expertise with technology for more effective recovery,” Dr. Allen C.L. Hsu, Consultant, said.
Precision Oncology: Personalized Therapy with Tumor Organoids
CancerFree Biotech Ltd. has advanced precision oncology with its liquid biopsy–derived tumor organoid system, which grows patient-specific organoids from 20 milliliters of blood to guide drug selection and avoid unnecessary side effects.
“We have shortened testing from six weeks to just three by embedding AI throughout our workflow and leveraging our extensive organoid image database to refine drug screening. In addition, we have begun a research collaboration with the Okinawa Institute of Science and Technology, marking our entry into the Japanese market,” Melody Shiau, Business Development Associate, noted.
Telemedicine: Scalable, Portable, and Patient-Centered
QT Medical, Inc. has focused on making hospital-grade PCA 500 12-lead ECG System more accessible outside traditional clinical settings. The platform is a compact, wireless, FDA-cleared system suitable for home care, telehealth, clinical trials, rural health, and conventional hospitals. “We seek strategic partnerships with healthcare providers, telehealth platforms, clinical trial organizations, government health agencies, and AI/digital health firms to expand remote and predictive diagnostics capabilities.” Frank Chang, Sales Manager, stated.
Medimaging Integrated Solution Inc. (MiiS) specializes in optical sensing and medical imaging processing, offering vertically integrated design and manufacturing from components to end products. The company has an in-house regulatory team to enable global approvals such as FDA and positions it as a one-stop solution provider. Stefan Cheng, President of MiiS, remarked “We aim to lead the future of AI-enabled medical diagnosis, emphasize technologies like AI, robotics, and image sensing as essential for the next generation healthcare.”
imedtac Co., Ltd. presented an AI-powered millimeter-wave radar that non-invasively monitors vital signs such as respiration and heart rate, particularly useful in eldercare and ICU environments where contact-based monitoring can be challenging. ”We identify two major trends driving demand: Ongoing labor shortages among doctors and nurses in North America. The other is a gap between available medical technologies globally. Michael Lo, Sales Head, indicated.
Hukui Biotechnology Co., Ltd., a Taiwanese medical devices CDMO company established in 2013, highlighted the company’s dual focus on contract manufacturing and direct sales. Key achievements include partnerships with a major Taiwanese brand to produce a wireless ultrasound scanner and with a U.S. company for a disposable endoscope. The company has now launched its own patented “VitaShine Gamma Light”. “We are aiming at dementia and Alzheimer’s prevention, and are actively seeking U.S. distributors to penetrate the American market.” Michael Kuo, Co-Founder and CEO, noted.
A Global Vision for Health Innovation
At Taiwan Expo USA 2025, the Smart Healthcare Pavilion highlighted Taiwan’s leadership in digital health and medical innovation while fostering collaboration with U.S. hospitals, tech companies, and research institutions. Showcasing AI diagnostics, precision oncology, telemedicine, and smart rehabilitation solutions, the pavilion demonstrated Taiwan’s commitment to patient-centered, scalable, and data-driven care.
Emphasizing innovative technology and clinical validation, Taiwan positions itself as a trusted global partner. As healthcare shifts toward predictive, personalized, and efficient solutions, Taiwan’s health-tech ecosystem is ready to drive innovation, strengthen international partnerships, and help shape the future of intelligent healthcare worldwide. [Ad by TITA]
Related posts:
Thai Biotech Industry’s Promising Potential: Taiwan Works Toward Strengthening APAC Ties at Bio Asia Pacific—Collaboration is Key
Key Trends in the Pharmaceutical Pipeline for 2024 — Part I: Transformative R&D Growth Driven by Breakthroughs in Oncology, Neurological, and Metabolic Therapies
Scaling Trust and Impact in Digital Health Through Real-World Innovations and AI Strategies
Rethinking Reimbursement: How Real-World Data Can Reshape the Future of Drug Access
